Skip to main content

Advertisement

SpringerLink
Log in

New treatments for diabetic neuropathy: Symptomatic treatments

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Painful diabetic neuropathy is a common distressing and challenging condition. The mechanism or mechanisms involved in its pathogenesis continue to elude clinical scientists. As with other conditions of painful distal symmetrical neuropathic conditions, pain relief involves the use of a variety of analgesic and neuroleptic drugs, aimed at reducing either central responses to painful stimuli or at dampening spontaneous irritability of affected neurons. More recently, several therapies directed at putative pathologic mechanisms specific to painful diabetic neuropathy have evolved. These include vasodilators, protein kinase C β inhibition, antioxidants, and novel aldose reductase inhibitors. Preliminary clinical studies of these therapies have at present involved small numbers of patients; however, the results have been encouraging. This article considers the clinical aspects of diagnosis and management of chronic painful diabetic neuropathy, focusing on existing and newer therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Dyck PJ, Kratz KM, Karnes JL, et al.: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817–824. [Published erratum appears in Neurology 1993, 43:2345.]

    PubMed  CAS  Google Scholar 

  2. Tesfaye S, Stevens LK, Stephenson JM, et al.: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996, 39:1377–1384.

    Article  PubMed  CAS  Google Scholar 

  3. Veves A, Manes C, Murray HJ, et al.: Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care 1993, 16:1187–1189.

    Article  PubMed  CAS  Google Scholar 

  4. Galer BS, Gianas A, Jensen MP: Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000, 47:123–128.

    Article  PubMed  CAS  Google Scholar 

  5. Young MJ, Boulton AJ, Macleod AF, et al.: A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993, 36:150–154.

    Article  PubMed  CAS  Google Scholar 

  6. Lacomis D: Small-fiber neuropathy. Muscle Nerve 2002, 26:173–188.

    Article  PubMed  Google Scholar 

  7. Stewart JD, Nguyen DM, Abrahamowicz M: Quantitative sweat testing using acetylcholine for direct and axon reflex mediated stimulation with silicone mold recording; controls versus neuropathic diabetics. Muscle Nerve 1994, 17:1370–1377.

    Article  PubMed  CAS  Google Scholar 

  8. Hirai A, Yasuda H, Joko M, et al.: Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves. J Neurol Sci 2000, 172:55–62.

    Article  PubMed  CAS  Google Scholar 

  9. Llewelyn JG, Thomas PK, Fonseca V, et al.: Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol (Berl) 1986, 72:157–163.

    Article  CAS  Google Scholar 

  10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–286.

  11. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial [no authors listed]. Ann Neurol 1995, 38:869–880.

  12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–853.

  13. Effect of 6 months of strict metabolic control on eye and kidney function in insulin-dependent diabetics with background retinopathy. Steno study group [no authors listed]. Lancet 1982, 1:121–124.

  14. Boulton AJ, Drury J, Clarke B, Ward JD: Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982, 5:386–390.

    Article  PubMed  CAS  Google Scholar 

  15. Samanta A, Burden AC: Rapid improvement in pain of diabetic neuropathy. Using an open loop intravenous insulin infusion system. Practical Diabetes 1985, 2:22–23.

    Article  Google Scholar 

  16. Watson CP: The treatment of neuropathic pain: antidepressants and opioids. Clin.J Pain 2000, 16:S49-S55.

    PubMed  CAS  Google Scholar 

  17. Ulugol A, Karadag HC, Tamer M, et al.: Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocininduced diabetic rats. Neurosci Lett 2002, 328:129–132.

    Article  PubMed  CAS  Google Scholar 

  18. Gomez-Perez FJ, Rull JA, Dies H, et al.: Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 1985, 23:395–400.

    Article  PubMed  CAS  Google Scholar 

  19. Gomez-Perez FJ, Choza R, Rios JM, et al.: Nortriptylinefluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996, 27:525–529.

    PubMed  CAS  Google Scholar 

  20. Max MB, Kishore-Kumar R, Schafer SC, et al.: Efficacy of desipramine in painful diabetic neuropathy: a placebocontrolled trial. Pain 1991, 45:3–9.

    Article  PubMed  CAS  Google Scholar 

  21. Max MB, Lynch SA, Muir J, et al.: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992, 326:1250–1256.

    Article  PubMed  CAS  Google Scholar 

  22. Morello CM, Leckband SG, Stoner CP, et al.: Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999, 159:1931–1937.

    Article  PubMed  CAS  Google Scholar 

  23. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83:389–400.

    Article  PubMed  CAS  Google Scholar 

  24. Sindrup SH, Gram LF, Brosen K, et al.: The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990, 42:135–144.

    Article  PubMed  CAS  Google Scholar 

  25. Sindrup SH, Bjerre U, Dejgaard A, et al.: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992, 52:547–552.

    Article  PubMed  CAS  Google Scholar 

  26. Tremont-Lukats IW, Megeff C, Backonja MM: Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000, 60:1029–1052.

    Article  PubMed  CAS  Google Scholar 

  27. Chadda VS, Mathur MS: Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 1978, 26:403–406.

    PubMed  CAS  Google Scholar 

  28. Saudek CD, Werns S, Reidenberg MM: Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 1977, 22:196–199.

    PubMed  CAS  Google Scholar 

  29. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano CO: Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969, 5:215–218.

    Article  PubMed  CAS  Google Scholar 

  30. Wilton TD: Tegretol in the treatment of diabetic neuropathy. S Afr Med J 1974, 48:869–872.

    PubMed  CAS  Google Scholar 

  31. Backonja MM: Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, doubleblind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia 1999, 40(suppl 6):S57-S59.

    Article  PubMed  CAS  Google Scholar 

  32. Gorson KC, Schott C, Herman R, et al.: Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999, 66:251–252.

    PubMed  CAS  Google Scholar 

  33. Eisenberg E, Alon N, Ishay A, et al.: Lamotrigine in the treatment of painful diabetic neuropathy. Eur J Neurol 1998, 5:167–173.

    Article  PubMed  Google Scholar 

  34. Eisenberg E, Lurie Y, Braker C, et al.: Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001, 57:505–509.

    PubMed  CAS  Google Scholar 

  35. Johnson BA, Ait-Daoud N, Bowden CL, et al.: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003, 361:1677–1685.

    Article  PubMed  CAS  Google Scholar 

  36. Edwards K, Glantz MJ, Button J: Efficacy and safety of topiramate in the treatment of painful neuropathy: a double-blind placebocontrolled study [abstract]. Neurology 2000, 54:A81.

    Google Scholar 

  37. Vinik A, Pittenger G, Barcus NI, et al.: Topiramate improves Cfiber neuropathy and dysmetabolic syndrome in diabetes [abstract]. J Peripher Nerv Syst 2003, 8:201.

    Google Scholar 

  38. Bach FW, Jensen TS, Kastrup J, et al.: The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain 1990, 40:29–34.

    Article  PubMed  CAS  Google Scholar 

  39. Kastrup J, Angelo H, Petersen P, et al.: Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. BMJ 1986, 292:173.

    Article  PubMed  CAS  Google Scholar 

  40. Kastrup J, Petersen P, Dejgard A, et al.: Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy? Pain 1987, 28:69–75.

    Article  PubMed  CAS  Google Scholar 

  41. Ackerman WE III, Colclough GW, Juneja MM, Bellinger K: The management of oral mexiletine and intravenous lidocaine to treat chronic painful symmetrical distal diabetic neuropathy. J Ky Med Assoc 1991, 89:500–501.

    PubMed  Google Scholar 

  42. Stracke H, Meyer UE, Schumacher HE, Federlin K: Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992, 15:1550–1555.

    Article  PubMed  CAS  Google Scholar 

  43. Wright JM, Oki JC, Graves LIII: Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997, 31:29–34.

    PubMed  CAS  Google Scholar 

  44. Robbins W: Clinical applications of capsaicinoids. Clin J Pain 2000, 16:S86-S89.

    Article  PubMed  CAS  Google Scholar 

  45. Scheffler NM, Sheitel PL, Lipton MN: Treatment of painful diabetic neuropathy with capsaicin 0.075%. J Am Podiatr Med Assoc 1991, 81:288–293.

    PubMed  CAS  Google Scholar 

  46. Tandan R, Lewis GA, Badger GB, Fries TJ: Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care 1992, 15:15–18.

    Article  PubMed  CAS  Google Scholar 

  47. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group [no authors listed]. Arch Intern Med 1991, 151:2225–2229.

  48. Chad DA, Aronin N, Lundstrom R, et al.: Does capsaicin relieve the pain of diabetic neuropathy? Pain 199, 42:387–388.

  49. Harati Y, ed: Endocrinology & Metabolism. Philadelphia: WB Saunders; 1996.

    Google Scholar 

  50. Zhang WY, Li Wan PA: The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994, 46:517–522.

    Article  PubMed  CAS  Google Scholar 

  51. Biesbroeck R, Bril V, Hollander P, et al.: A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 1995, 12:111–120.

    PubMed  CAS  Google Scholar 

  52. Levy DM, Abraham RR, Tomlinson DR: Topical capsaicin in the treatment of painful diabetic neuropathy. N Engl J Med 1991, 324:776–777.

    Article  PubMed  CAS  Google Scholar 

  53. Hart-Gouleau S, Gammaitoni A, Gaeler B, et al.: Effectiveness and safety of the lidocaine patch 5% in patients with painful neuropathy: a prospective, open-label pilot study. Paper presented at the 5th International Conference on the Mechanisms and Treatment of Neuropathic Pain. Southampton, Bermuda; November 21, 2002.

  54. Foster AV, Eaton C, McConville DO, Edmonds ME: Application of OpSite film: a new and effective treatment of painful diabetic neuropathy. Diabet Med 1994, 11:768–772.

    PubMed  CAS  Google Scholar 

  55. Malik RA, Newrick PG, Sharma AK, et al.: Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989, 32:92–102.

    Article  PubMed  CAS  Google Scholar 

  56. Tesfaye S, Malik R, Harris N, et al.: Arteriovenous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996, 39:329–335.

    PubMed  CAS  Google Scholar 

  57. Cameron NE, Eaton SE, Cotter MA, Tesfaye S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001, 44:1973–1988.

    Article  PubMed  CAS  Google Scholar 

  58. Reja A, Tesfaye S, Harris ND, Ward JD: Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med 1995, 12:307–309.

    Article  PubMed  CAS  Google Scholar 

  59. Malik RA, Williamson S, Abbott C, et al.: Effect of angiotensinconverting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998, 352:1978–1981.

    Article  PubMed  CAS  Google Scholar 

  60. Sasaki T, Yasuda H, Maeda K, Kikkawa R: Hyperalgesia and decreased neuronal nitric oxide synthase in diabetic rats. Neuroreport 1998, 9:243–247.

    PubMed  CAS  Google Scholar 

  61. Rodella L, Rezzani R, Corsetti G, Bianchi R: Nitric oxide involvement in the trigeminal hyperalgesia in diabetic rats. Brain Res 2000, 865:112–115.

    Article  PubMed  CAS  Google Scholar 

  62. Yuen KC, Baker NR, Rayman G: Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 2002, 25:1699–1703. First study to describe the use of ISDN spray (an NO donor) is effective in reducing diabetic neuropathic pain.

    Article  PubMed  CAS  Google Scholar 

  63. Rayman G, Baker NR, Krishnan ST: Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care 2003, 26:2697–2698. Further work with NO donor (GTN patches) describing the data on 18 patients with painful diabetic neuropathy improving neuropathic pain.

    Article  PubMed  Google Scholar 

  64. Jaspan JB, Towle VL, Maselli R, Herold K: Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism 1986, 35:83–92.

    Article  PubMed  CAS  Google Scholar 

  65. Foppiano M, Lombardo G: Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet 1997, 349:399–400.

    Article  PubMed  CAS  Google Scholar 

  66. Davis EJ: Pfizer suspends zenarestat [press release]. New York, NY: Pfizer; October 18, 2000.

    Google Scholar 

  67. Hotta N, Toyota T, Matsuoka K, et al.: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebocontrolled double-blind parallel group study. Diabetes Care 2001, 24:1776–1782.

    Article  PubMed  CAS  Google Scholar 

  68. Ametov AS, Barinov A, Dyck PJ, et al.: The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003, 26:770–776. This trial demonstrated that intravenous ALA at a dose of 600 mg for 14 treatments 5 d/wk resulted in significant improvement in neuropathic symptoms including pain assessed by several independent scoring methods.

    Article  PubMed  CAS  Google Scholar 

  69. Ziegler D, Hanefeld M, Ruhnau KJ, et al.: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995, 38:1425–1433.

    Article  PubMed  CAS  Google Scholar 

  70. Ziegler D, Hanefeld M, Ruhnau KJ, et al.: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999, 22:1296–1301.

    Article  PubMed  CAS  Google Scholar 

  71. Cotter MA, Jack AM, Cameron NE: Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2002, 103:311–321.

    CAS  Google Scholar 

  72. Litchy W, Dyck P, Tesfaye S, et al.: Diabetic peripheral neuropathy (DPN) assessed by neurological examination and composite scores is improved with LY333531 treatment [abstract]. The MBBQ Study Group. Diabetes 2002, 45:197. A placebo-controlled dose-finding clinical trial of LY333531 (PKC β inhibitor) in 205 patients with symptomatic diabetic peripheral neuropathy. LY333531 in a dose of 32 and 64 mg seemed to improve neuropathy symptoms assessed by clinical examination and composite scores.

    Google Scholar 

  73. Criner TM, Perdun CS: Dextromethorphan and diabetic neuropathy. Ann Pharmacother 1999, 33:1221–1223.

    Article  PubMed  CAS  Google Scholar 

  74. Sang CN, Booher S, Gilron I, et al.: Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002, 96:1053–1061.

    Article  PubMed  CAS  Google Scholar 

  75. Backonja M: Managing painful diabetic neuropathy. Hosp Pract (Off Ed) 1999, 34:79–88.

    CAS  Google Scholar 

  76. Harati Y, Gooch C, Swenson M, et al.: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998, 50:1842–1846.

    PubMed  CAS  Google Scholar 

  77. Harati Y, Gooch C, Swenson M, et al.: Maintenance of the longterm effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000, 14:65–70. Opioid analgesics are widely used in the treatment of diabetic neuropathy. This recent trial confirms the long-term effectiveness and maintenance of tramadol.

    Article  PubMed  CAS  Google Scholar 

  78. Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003, 60:927–934. This recent randomized control trial shows that controlled-release oxycodone can be effective in the treatment of symptomatic diabetic neuropathy.

    PubMed  CAS  Google Scholar 

  79. Abuaisha BB, Costanzi JB, Boulton AJ: Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998, 39:115–121.

    Article  PubMed  CAS  Google Scholar 

  80. Kumar D, Marshall HJ: Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997, 20:1702–1705.

    Article  PubMed  CAS  Google Scholar 

  81. Kumar D, Alvaro MS, Julka IS, Marshall HJ: Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief. Diabetes Care 1998, 21:1322–1325.

    Article  PubMed  CAS  Google Scholar 

  82. North RB, Kidd DH, Zahurak M, et al.: Spinal cord stimulation for chronic, intractable pain: experience over two decades. Neurosurgery 1993, 32:384–394.

    Article  PubMed  CAS  Google Scholar 

  83. Melzack R, Wall PD: Pain mechanisms: a new theory. Science 1965, 150:971–979.

    Article  PubMed  CAS  Google Scholar 

  84. Tesfaye S, Watt J, Benbow SJ, et al.: Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996, 348:1698–1701.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Centre, Ipswich Hospital, Heath Road, IP5 4PD, Suffolk, UK

    Singhan T. M. Krishnan MRCP & Gerry Rayman MD, FRCP

Authors
  1. Singhan T. M. Krishnan MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerry Rayman MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krishnan, S.T.M., Rayman, G. New treatments for diabetic neuropathy: Symptomatic treatments. Curr Diab Rep 3, 459–467 (2003). https://doi.org/10.1007/s11892-003-0008-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-003-0008-y

Keywords

Search

Navigation